Hematopoietic Stem Cell Transplantation for X-Linked Thrombocytopenia With Mutations in the WAS gene

Journal of Clinical Immunology

Volumn 35, Issue 1, 2015, Pages 15-21

  Oshima, Koichi ^a   Imai, Kohsuke ^b   Albert, Michael H ^c   Bittner, Tanja C ^c   Strauss, Gabriele ^d   Filipovich, Alexandra H ^e   Morio, Tomohiro ^b   Kapoor, Neena ^f   Dalal, Jignesh ^g   Schultz, Kirk R ^h   Casper, James T ⁱ   Notarangelo, Luigi D ^j,m   Ochs, Hans D ^k   Nonoyama, Shigeaki ^l  

^a KYOTO UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g CHILDREN S MERCY HOSPITAL   (United States)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ Children s Hospital of Wisconsin   (United States)

^j UNIVERSITY OF BRESCIA   (Italy)

^k UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^l NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^m BOSTON CHILDREN S HOSPITAL   (United States)

more..

Author keywords

hematopoietic stem cell transplantation; Wiskott Aldrich syndrome; X linked thrombocytopenia

Indexed keywords

CYCLOSPORIN A; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; RITUXIMAB; TACROLIMUS; WAS PROTEIN, HUMAN; WISKOTT ALDRICH SYNDROME PROTEIN;

ADOLESCENT; ADULT; ARTICLE; ASPERGILLOSIS; CHILD; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; DISEASE SEVERITY; ENGRAFTMENT; FEMALE; GENE MUTATION; GERMANY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; JAPAN; MALE; MEDICAL RECORD REVIEW; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; THROMBOCYTOPENIA; UNITED STATES; WISKOTT ALDRICH SYNDROME; X CHROMOSOME LINKED DISORDER; ADVERSE EFFECTS; COHORT ANALYSIS; DISEASE FREE SURVIVAL; GENETIC DISEASES, X-LINKED; GENETICS; GRAFT VS HOST DISEASE; INFANT; KAPLAN MEIER METHOD; MORTALITY; MUTATION; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE-FREE SURVIVAL; GENETIC DISEASES, X-LINKED; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; MALE; MUTATION; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; WISKOTT-ALDRICH SYNDROME; WISKOTT-ALDRICH SYNDROME PROTEIN; YOUNG ADULT;

EID: 84925493986     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-014-0105-5     Document Type: Article

References (12)

1. Villa A, Notarangelo L, Macchi P, Mantuano E, Cavagni G, Brugnoni D, et al. X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nat Genet. 1995;9(4):414–7. doi:10.1038/ng0495-414.
2. Albert M, Notarangelo L, Ochs H. Clinical spectrum, pathophysiology and treatment of the Wiskott-Aldrich syndrome. Curr Opin Hematol. 2010. doi:10.1097/MOH.0b013e32834114bc.
3. Kobayashi R, Ariga T, Nonoyama S, Kanegane H, Tsuchiya S, Morio T, et al. Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan. Br J Haematol. 2006;135(3):362–6. doi:10.1111/j.1365-2141.2006.06297.x.
4. Ozsahin H, Cavazzana-Calvo M, Notarangelo L, Schulz A, Thrasher A, Mazzolari E, et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood. 2008;111(1):439–45. doi:10.1182/blood-2007-03-076679.
5. Moratto D, Giliani S, Bonfim C, Mazzolari E, Fischer A, Ochs H, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980–2009: an international collaborative study. Blood. 2011;118(6):1675–84. doi:10.1182/blood-2010-11-319376.
6. Albert M, Bittner T, Nonoyama S, Notarangelo L, Burns S, Imai K, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood. 2010;115(16):3231–8. doi:10.1182/blood-2009-09-239087.
7. Imai K, Morio T, Zhu Y, Jin Y, Itoh S, Kajiwara M, et al. Clinical course of patients with WASP gene mutations. Blood. 2004;103(2):456–64. doi:10.1182/blood-2003-05-1480.
8. den Dunnen J, Antonarakis S. Nomenclature for the description of human sequence variations. Hum Genet. 2001;109(1):121–4. doi:10.1007/s004390100505.
9. Jin Y, Mazza C, Christie J, Giliani S, Fiorini M, Mella P, et al. Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood. 2004;104(13):4010–9. doi:10.1182/blood-2003-05-1592.
10. Otsubo K, Kanegane H, Nomura K, Miyawaki T, Ishizawa S. Atypical lymphoproliferative disorder in a patient with X-linked thrombocytopenia. Pediatr Blood Cancer. 2008;51(3):443–4. doi:10.1002/pbc.21644.
11. Inoue H, Kurosawa H, Nonoyama S, Imai K, Kumazaki H, Matsunaga T, et al. X-linked thrombocytopenia in a girl. Br J Haematol. 2002;118(4):1163–5. doi:10.1046/j.1365-2141.2002.03740.x.
12. Hoshino A, Shimizu M, Matsukura H, Sakaki-Nakatsubo H, Nomura K, Miyawaki T, et al. Allogeneic bone marrow transplantation appears to ameliorate IgA nephropathy in a patient with X-linked thrombocytopenia. J Clin Immunol. 2014;34(1):53–7. doi:10.1007/s10875-013-9964-4.